Publications by authors named "Wim Noel"

Claim this Profile
R
Real-World Assessment of Systemic Disease Activity in Seropositive and Seronegative Patients with Sjögren's Disease and Association with Patient-Reported Outcomes.
Jacques-Eric Gottenberg, Raphaele Seror, Nicola Massey, Megan Hughes, Victoria Barton, Wim Noel

Rheumatol Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reporting of management and outcomes in the hemolytic disease of the fetus and newborn: a systematic literature review.
Ejt Verweij, Enrico Lopriore, Marie Fitzgibbon, Jenny Noack, Thomas Wilke, Wim Noel

J Perinatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome measures in CIDP: A scoping and mapping review.
Yusuf A Rajabally, Giorgio Maria Boggia, Danielle Riley, Sam Riley, Judith Peatman, Wim Noel

J Neurol Sci· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Multinational Survey of Chronic Inflammatory Demyelinating Polyneuropathy: Disease Characteristics and Therapeutic Landscape.
Luis Querol, Simon Rinaldi, Andras Borsi, Giorgio Maria Boggia, Jonathan de Courcy, Wim Noel

J Peripher Nerv Syst· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact and management of warm autoimmune haemolytic anaemia associated with systemic lupus erythematosus.
Guillermo J Pons-Estel, Marta Mosca, Daniel J Wallace, Federico Zazzetti, Ann Leon

Autoimmun Rev· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient Profiles in Randomized Controlled Trials Versus a Real-World Study in Psoriatic Arthritis: Scoping Review and Metaanalysis.
Gelsomina Alle, Clementina Lopez-Medina, Stefan Siebert, Frédéric Lavie, Wim Noel

J Rheumatol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival and Treatment Patterns Among Patients With Warm Autoimmune Hemolytic Anemia in Sweden: A Nationwide Population-based Study.
Honar Cherif, Qian Cai, Concetta Crivera, Ann Leon, Iffat Rahman, Wim Noel

Eur J Haematol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of diagnosis delay on European patients with generalised myasthenia gravis.
Elena Cortés-Vicente, Andras J Borsi, Charlotte Gary, Wim G J Noel, Jennifer M S Lee

Ann Clin Transl Neurol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing Efficacy of Guselkumab versus Ustekinumab in Patients with Psoriatic Arthritis: An Adjusted Comparison Using Individual Patient Data from the DISCOVER and PSUMMIT Trials.
Pushpike Thilakarathne, Agata Schubert, Steve Peterson, Wim Noel, Barkha P Patel

Rheumatol Ther· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data.
Arno W R Van Kuijk, Mike T Nurmohamed, Stefan Siebert, Paul Bergmans, Kurt de Vlam

Rheumatology (Oxford)· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study.
Laure Gossec, Elke Theander, Soumya D Chakravarty, Paul Bergmans, Frederic Lavie

Arthritis Res Ther· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study.
Laure Gossec, Stefan Siebert, Paul Bergmans, Kurt de Vlam, Elisa Gremese

Arthritis Res Ther· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study.
Laure Gossec, Stefan Siebert, Paul Bergmans, Kurt de Vlam, Elisa Gremese

Ann Rheum Dis· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence, effectiveness and safety of ustekinumab compared to TNF inhibitors in psoriatic arthritis within the Italian PsABio cohort.
Elisa Gremese, Francesco Ciccia, Carlo Selmi, Giovanna Cuomo, Rosario Foti

Clin Exp Rheumatol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of PsA phenotypes with machine learning analytics using data from two phase III clinical trials of guselkumab in a bio-naïve population of patients with PsA.
Pascal Richette, Marijn Vis, Sarah Ohrndorf, William Tillett, Julio Ramírez, Wim Noel

RMD Open· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis.
Laura C Coates, Christopher T Ritchlin, Laure Gossec, Philip S Helliwell, Proton Rahman

Rheumatology (Oxford)· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study.
Laure Gossec, Stefan Siebert, Paul Bergmans, Kurt de Vlam, Elisa Gremese

Ann Rheum Dis· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk Management Plans: reassessment of safety concerns based on Good Pharmacovigilance Practices Module V (Revision 2)-a company experience.
Suzan Esslinger, Linda Quinn, Sami Sampat, Marijo Otero-Lobato, Wim Noël

J Pharm Health Care Sci· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS).
Laura C Coates, Laure Gossec, Elke Theander, Paul Bergmans, Marlies Neuhold

Ann Rheum Dis· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results.
Josef S Smolen, Stefan Siebert, Tatiana V Korotaeva, Carlo Selmi, Paul Bergmans

Ann Rheum Dis· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to: Persistence of biologic treatments in psoriatic arthritis: a population-based study in Sweden.
Kirk Geale, Ingrid Lindberg, Emma C Paulsson, E Christina M Wennerström, Anna Tjärnlund, Wim Noel

Rheumatol Adv Pract· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence of biologic treatments in psoriatic arthritis: a population-based study in Sweden.
Kirk Geale, Ingrid Lindberg, Emma C Paulsson, E Christina M Wennerström, Anna Tjärnlund, Wim Noel

Rheumatol Adv Pract· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-approval Safety Surveillance Study of Golimumab in the Treatment of Rheumatic Disease Using a United States Healthcare Claims Database.
Najat J Ziyadeh, Anja Geldhof, Wim Noël, Marijo Otero-Lobato, Suzan Esslinger

Clin Drug Investig· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of the golimumab educational program in ensuring healthcare professionals' awareness of risks described in the European risk management plan.
Lauren Felo, Marijo Otero-Lobato, Anja Geldhof, Wim Noël

Ther Adv Drug Saf· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alternatively activated myeloid cells limit pathogenicity associated with African trypanosomiasis through the IL-10 inducible gene selenoprotein P.
Tom Bosschaerts, Martin Guilliams, Wim Noel, Michel Hérin, Raymond F Burk

J Immunol· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis